ESH Video

7th International Conference on Myeloproliferative Neoplasms

SESSION I – GENETIC AND CELLULAR PATHOGENESIS OF MPNs

Splicing factor-mutant myeloid neoplasms – Mario Cazzola     
Causes of myeloproliferative disordersMary-Frances McMullin
Novel oncogenic mechanisms in myeloproliferative neoplasms: the mutated chaperon calreticulin embracing cytokine receptors – Stefan N. Constantinescu
The genomic basis of acute lymphoblastic leukaemiaCharles G. Mullighan
The genomics of MPNsPeter Campbell

SESSION II – NOVEL MPN THERAPEUTICS

Epigenetic alterations and therapeutic targeting in MPNRoss L. Levine
Role of megakaryocytes in the MPNsJohn D. Crispino
Molecular insights into regulation of JAK2 in MPNOlli Silvennoinen
Using molecular information to inform patient management – Alessandro M. Vannucchi
Targeting JAK2 – Have we arrived?Thomas Radimerski

 SESSION III – MECHANISMS OF MYELOID TRANSFORMATION AND PROGRESSION

Cellular and molecular response to interferon therapy in PV and ETJosef T. Prchal
Functional and molecular dissection of molecular drivers in MPN – Ann Mullally
MPN pathogenesis and JAK/STAT signalling – Tony R. Green
Bone marrow niches for HSCs in MPN – Simón Méndez-Ferrer
What is new about the pathogenesis of thrombosis in MPN in 2016? – Chloé James

SESSION IV – MURINE MODELING OF MPN

Stem cell origin of myeloproliferative neoplasms – Radek Skoda
Modeling predisposition to familial MPNIsabelle Plo
Preclinical analysis of linsitinib for the treatment of polycythemia vera – Heike L. Pahl       
Modeling the calreticulin disease in mice – William Vainchenker       

SESSION V – TARGETING THE MPN STEM CELL

RNA rewriting, recoding and rewiring in myeloproliferative neoplasms stem cells – Catriona Jamieson
Optimize transplant results in myelofibrosis – Nicolaus Kröger
Using single cell biology to identify stem cell fate regulators in haematological malignanciesDavid Kent
The effects of specialized microenvironments on haematopoiesis in myelofibrosisRonald Hoffman

SESSION VI – RECENT ADVANCES IN MANAGEMENT

Natural history and risk stratification of prefibrotic myelofibrosisGiovanni Barosi
An update of interferon trials in MPN – Jean-Jacques Kiladjian        

SESSION VII – RECENT ADVANCES IN MANAGEMENT 2

Rethinking the treatment recommendations in low-risk PVTiziano Barbui
 
Next generation MPN managementRuben A. Mesa 
Promises and pitfalls of JAK inhibitor therapy – Claire Harrison         

 

 
Clinical Updates on Acute Leukemias 6th International Conference on Myelodysplastic Syndromes ESH - GR-EX 2nd International Symposium on Red Blood Cells: Genesis and Pat...